|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan SH and Wang LH: Regulation of cancer
metastasis by microRNAs. J Biomed Sci. 22:92015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng
H and Lai M: MiR-148a promotes apoptosis by targeting Bcl-2 in
colorectal cancer. Cell Death Differ. 18:1702–1710. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakamoto N, Naito Y, Oue N, Sentani K,
Uraoka N, Oo Zarni H, Yanagihara K, Aoyagi K, Sasaki H and Yasui W:
MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and
indicates tumor invasiveness and poor prognosis. Cancer Sci.
105:236–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Braconi C, Huang N and Patel T:
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor
suppressor gene expression by interleukin-6 in human malignant
cholangiocytes. Hepatology. 51:881–890. 2010.PubMed/NCBI
|
|
9
|
Heo MJ, Kim YM, Koo JH, Yang YM, An J, Lee
SK, Lee SJ, Kim KM, Park JW and Kim SG: microRNA-148a dysregulation
discriminates poor prognosis of hepatocellular carcinoma in
association with USP4 overexpression. Oncotarget. 5:2792–2806.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bloomston M, Frankel WL, Petrocca F,
Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C and Croce
CM: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Szafranska AE, Davison TS, John J, Cannon
T, Sipos B, Maghnouj A, Labourier E and Haln SA: MicroRNA
expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhan Q, Fang Y, Deng X, Chen H, Jin J, Lu
X, Peng C, Li H and Shen B: The interplay between miR-148a and
DNMT1 might be exploited for pancreatic cancer therapy. Cancer
Invest. 33:267–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang R, Li M, Zang W, Chen X, Wang Y, Li
P, Du Y, Zhao G and Li L: MiR-148a regulates the growth and
apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour
Biol. 35:837–44. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liffers ST, Munding JB, Vogt M, Kuhlmann
JD, Verdoodt B, Nambiar S, Maghnouj A, Mimohammadsadegh A, Hahn SA
and Tannapfel A: MicroRNA-148a is down-regulated in human
pancreatic ductal adenocarcinomas and regulates cell survival by
targeting CDC25B. Lab Invest. 91:1472–1479. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng H, Wang Y, Su J, Liang H, Zhang CY,
Chen X and Yao W: MicroRNA-148a suppresses the proliferation and
migration of pancreatic cancer cells by down-regulating ErbB3.
Pancreas. 45:1263–1271. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lopez-Serra P and Esteller M: DNA
methylation-associated silencing of tumor-suppressor microRNAs in
cancer. Oncogene. 31:1609–1622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie K, Liu J, Chen J, Dong J, Ma H, Liu Y
and Hu Z: Methylation-associated silencing of microRNA-34b in
hepatocellular carcinoma cancer. Gene. 543:101–107. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng DF, Kanai Y, Sawada M, Ushijima S,
Hiraoka N, Kosuge T and Hirohashi S: Increased DNA
methyltransferase 1 (DNMT1) protein expression in precancerous
conditions and ductal carcinomas of the pancreas. Cancer Sci.
96:403–408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li A, Omura N, Hong SM and Goggins M:
Pancreatic cancer DNMT1 expression and sensitivity to DNMT1
inhibitors. Cancer Biol Ther. 9:321–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu A, Xia J, Zuo J, Jin S, Zhou H, Yao L,
Huang H and Han Z: MicroRNA-148a is silenced by hypermethylation
and interacts with DNA methyltransferase 1 in gastric cancer. Med
Oncol. 29:2701–2709. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Long XR, He Y, Huang C and Li J:
MicroRNA-148a is silenced by hypermethylation and interacts with
DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J
Oncol. 44:1915–1922. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng L, Liu Z, Xiao J, Tu Y, Wan Z, Xiong
H, Li Y and Xiao W: MicroRNA-148a suppresses epithelial-mesenchymal
transition and invasion of pancreatic cancer cells by targeting
Wnt10b and inhibiting the Wnt/β-catenin signaling pathway. Oncol
Rep. 38:301–308. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sanger F, Nicklen S and Coulson AR: DNA
sequencing with chain-terminating inhibitors. Proc Natl Acad Sci
USA. 74:5463–5467. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumaki Y, Oda M and Okano M: QUMA:
Quantification tool for methylation analysis. Necleic Acids Res.
36:W170–W175. 2008. View Article : Google Scholar
|
|
26
|
Bock C, Reither S, Mikeska T, Paulsen M,
Walter J and Lengauer T: BiQ Analyzer: Visualization and quality
control for DNA methylation data from bisulfite sequencing.
Bioinformatics. 21:4067–4068. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee J, Shin MK, Ryu DK, Kim S and Ryu WS:
Insertion and deletion mutagenesis by overlap extension PCR.
Methods Mol Biol. 634:137–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bestor TH: The DNA methyltransferases of
mammals. Hum Mol Genet. 9:2395–2402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cowan RW and Maitra A: Genetic progression
of pancreatic cancer. Cancer J. 20:80–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yonemori K, Kurahara H, Maemura K and
Natsugoe S: MicroRNA in pancreatic cancer. J Hum Genet. 62:33–40.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang L, Luo P, Song Q and Fei X:
DNMT1/miR-200a/GOLM1 signaling pathway regulates lung
adenocarcinoma cells proliferation. Biomed Pharmacother.
99:839–847. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ning X, Shi Z, Liu X, Zhang A, Han L,
Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation
silences the microRNA-200b/a/429 gene and promotes tumor
progression. Cancer Lett. 59:198–205. 2015. View Article : Google Scholar
|
|
33
|
Peng DF, Kanai Y, Sawada M, Ushijima S,
Hiraoka N, Kitazawa S and Hirohashi S: DNA methylation of multiple
tumor-related genes in association with overexpression of DNA
methyltransferase 1 (DNMT1) during multistage carcinogenesis of the
pancreas. Carcinogenesis. 27:1160–1168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu B, Song J, Luan J, Sun X, Bai J, Wang
H, Li A, Zhang L, Feng X and Du Z: Promoter methylation status of
tumor suppressor genes and inhibition of expression of DNA
methyltransferase 1 in non-small cell lung cancer. Exp Biol Med.
241:1531–1539. 2016. View Article : Google Scholar
|
|
35
|
Delpu Y, Lulka H, Sicard F, Saint-Laurent
N, Lopez F, Hanoun N, Buscail L, Cordelier P and Torrisani J: The
rescue of miR-148a expression in pancreatic cancer: An
inappropriate therapeutic tool. PLoS One. 8:e555132013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan FP, Zhou HK, Bu HQ, Chen ZQ, Zhang H,
Xu LP, Tang J, Yu QJ, Chu YQ, Pan J, et al: Emodin enhances the
demethylation by 5-AZa-CdR of pancreatic cancer tumor-suppressor
genes P16, RASSF1A and ppENK. Oncol Rep. 35:1941–1949. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Witkiewicz AK, Knudsen KE, Dicker AP and
Knudsen ES: The meaning of p16ink4a expression in tumors:
Functional significance, clinical associations and future
developments. Cell Cycle. 10:2497–2503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang L, Yang H, Li J, Hao J and Qian J:
ppENK gene methylation status in the development of pancreatic
carcinoma. Gastroenterol Res Pract. 2013:1309272013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vos MD, Martinez A, Elam C, Dallol A,
Taylor BJ, Latif F and Clark GJ: A role for the RASSF1A tumor
suppressor in the regulation of tubulin polymerization and genomic
stability. Cancer Res. 64:4244–4250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shivakumar L, Minna J, Sakamaki T, Pestell
R and White MA: The RASSF1A tumor suppressor blocks cell cycle
progression and inhibits cyclin D1 accumulation. Mol Cell Biol.
22:4309–4318. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Attri J, Srinivasan R, Majumdar S, Radotra
BD and Wig J: Alterations of tumor suppressor gene p16INK4a in
pancreatic ductal carcinoma. BMC Gastroenterol. 5:222005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dammann R, Schagdarsurengin U, Liu L, Otto
N, Gimm O, Dralle H, Boehm BO, Pfeifer GP and Hoang-Vu C: Frequent
RASSF1A promoter hypermethylation and K-ras mutations in pancreatic
carcinoma. Oncogene. 22:3806–3812. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fukushima N, Sato N, Ueki T, Rosty C,
Walter KM, Wilentz RE, Yeo CJ, Hruban RH and Goggins M: Aberrant
methylation of preproenkephalin and p16 genes in pancreatic
intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am
J Pathol. 160:1573–1581. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xiao WD, Li Y, Li XM, Cai J, Zeng LS and
Hu W: RNA interference-mediated silencing of the DNMT1 gene
inhibits cell proliferation in human pancreatic carcinoma cell line
BxPC-3. Shijie Huaren Xiaohua Zazhi. 19:3397–3401. 2011.(In
Chinese).
|
|
45
|
Sun J, Song Y, Wang Z, Wang G, Gao P, Chen
X, Gao Z and Xu H: Clinical significance of promoter region
hypermethylation of microRNA-148a in gastrointestinal cancers. Onco
Targets Ther. 7:853–863. 2014.PubMed/NCBI
|
|
46
|
Long XR, He Y, Huang C and Li J:
MicroRNA-148a is silenced by hypermethylation and interacts with
DNA methyltransferase in hepatocellular carcinogenesis. Int J
Oncol. 44:1915–1922. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li HP, Huang HY, Lai YR, Huang JX, Chang
KP, Hsueh C and Chang YS: Silencing of miRNA-148a by
hypermethylation activates the integrin-mediated signaling pathway
in nasopharyngeal carcinoma. Oncotarget. 5:7610–7624. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hanoun N, Delpu Y, Suriawinata AA, Bournet
B, Bureau C, Selves J, Tsongalis GJ, Dufresne M, Buscail L,
Cordelier P and Torrisani J: The silencing of microRNA 148a
production by DNA hypermethylation is an early event in pancreatic
carcinogenesis. Clin Chem. 56:1107–1118. 2010. View Article : Google Scholar : PubMed/NCBI
|
